Browse the evidence

Tirzepatide maintenance therapy (either at maximum tolerated dose or reduced to 5 mg) is designed to prevent the weight regain seen with placebo, with rescue protocols available for significant regain.

This paper outlines a trial testing if you can stay on a lower dose of tirzepatide (5mg) or stay on your highest effective dose to keep weight off, compared to stopping it. It also includes a safety net: if you regain more than half your lost weight, you get 'rescue' treatment.

Tirzepatide use is associated with a significantly lower risk of suicidal ideation or suicide attempts compared to other anti-obesity medications in a real-world cohort.

Current real-world evidence suggests that tirzepatide is not associated with an increased risk of suicide and may be associated with a lower risk compared to other anti-obesity medications. However, because this is an observational study, it does not prove causation. Patients with a history of suicidality were excluded, so this data does not apply to high-risk individuals. Consult your provider for personalized psychiatric risk assessment.

GLP-1 receptor agonist therapy for obesity effectively supports weight loss and improves quality of life, but long-term sustainability is undermined by high medication costs, inadequate multidisciplinary support, and significant side effects leading to discontinuation.

GLP-1 medications like Tirzepatide and Semaglutide are effective for weight loss and improving quality of life for many users. However, long-term success is not guaranteed. High costs and side effects are the main reasons people stop treatment. If you are considering or using these medications, be aware that discontinuation often leads to weight regain. Ensure you have a plan for managing costs and side effects, and consider seeking multidisciplinary support (dietary, psychological) to improve adherence and sustainability.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, achieves superior weight loss and hepatic steatosis reduction compared to semaglutide, with preliminary cardiovascular non-inferiority data.

If you have Type 2 Diabetes and fatty liver disease, ask your doctor about Tirzepatide. It is a newer medication that has shown superior weight loss and liver fat reduction compared to other GLP-1 drugs. While cardiovascular outcome data is still being finalized, it is a powerful option for managing both conditions.

Initiating anti-obesity medications more than 12 months after bariatric surgery is associated with a significantly lower risk of adverse events compared to initiation within the first 12 months.

If you are considering weight loss medication after bariatric surgery, current evidence suggests it may be safer to wait until at least 12 months have passed since your surgery. Starting medication earlier is associated with a much higher risk of adverse events, though this may be partly due to the natural recovery period of the surgery itself rather than the drug alone.

The menopausal transition is associated with a reduction in lean or muscle mass, with postmenopausal women showing approximately 5.7% lower muscle mass compared to premenopausal women, although this correlation may be confounded by aging and measurement limitations of DXA.

If you are going through menopause, expect a potential decline in muscle mass, particularly during the perimenopausal transition. This is not necessarily inevitable or irreversible. Focus on resistance training and adequate protein intake during this window, as it is a critical period where interventions may be most effective in preventing sarcopenia.

Older women may exhibit elevated fasted muscle protein synthesis (MPS) rates compared to younger women or age-matched men, but their MPS response to anabolic stimuli like resistance exercise or protein ingestion may be blunted.

As you age, your muscles may not respond as strongly to exercise and protein as they did when you were younger. This doesn't mean exercise is useless, but it does mean you may need to be more consistent and potentially adjust your protein intake to maximize muscle protein synthesis.

Support Vector Regression (SVR) machine learning models can accurately predict weight loss, fasting blood glucose, and HbA1c outcomes in Type 2 diabetic patients treated with Exenatide, enabling optimized nursing care and treatment decisions.

For nurses managing diabetic patients on Exenatide, using validated machine learning models (specifically SVR) can significantly improve the accuracy of predicting weight loss and glycemic control (HbA1c/Fasting Glucose). This allows for proactive adjustments to nursing care plans, dietary advice, and lifestyle interventions before complications arise, rather than reacting to poor outcomes after they occur.

Garcinia cambogia (Hydroxycitric acid/HCA) supplementation reduces visceral fat and improves fasting blood glucose and insulin sensitivity in overweight/obese individuals.

Garcinia cambogia (HCA) at 1,000 mg/day may help reduce visceral fat and improve blood sugar in overweight people, but it is not a magic bullet. It works by blocking fat synthesis and suppressing appetite.

Coleus forskohlii (Forskolin) supplementation reduces body fat, increases lean mass, and improves insulin sensitivity in overweight/obese men.

Coleus forskohlii (Forskolin) taken daily for 12 weeks may help reduce body fat and increase lean mass in overweight men, improving insulin sensitivity. It works by increasing cAMP, which stimulates fat breakdown.

Banaba leaf extract (Corosolic acid) and Resistant Maltodextrin (RMD) improve blood glucose control and insulin sensitivity through distinct mechanisms.

Banaba leaf extract and Resistant Maltodextrin (RMD) can improve blood glucose control and insulin sensitivity. Banaba works by promoting glucose uptake, while RMD delays carbohydrate absorption and increases SCFA production.

Carriers of the TCF7L2 rs7903146 T allele exhibit significantly attenuated weight loss and metabolic improvements compared to non-T allele (CC) carriers when following a partial meal replacement (pMR) hypocaloric diet.

If you have the TCF7L2 rs7903146 T allele, expect your weight loss to be roughly half as fast as someone with the CC genotype on a similar meal-replacement diet. Focus on metabolic health markers (blood sugar, insulin) as early wins, as these improve significantly even if the scale moves slower.

Pharmacotherapy with semaglutide (1 mg/week) and/or metformin (0.5g 3x/day) combined with lifestyle interventions produces weight loss comparable to low-carbohydrate diets and balanced diets at 3 months, despite potentially faster initial results.

Pharmacotherapy (semaglutide/metformin) combined with lifestyle changes is an effective weight loss strategy that yields similar results to dietary changes after 3 months. It is not just for 'severe' cases but can be a valid option for those struggling with diet alone.

Animal-based proteins provide a modest but statistically significant advantage in stimulating muscle protein synthesis (MPS) compared to plant-based proteins, primarily driven by higher leucine content and bioavailability.

If you are over 65, prioritize animal proteins (whey, milk, eggs) or ensure your plant protein is high-leucine (soy, pea blends) to maximize muscle growth. For younger adults, plant and animal proteins appear functionally equivalent for MPS when doses are matched.

The MPS advantage of animal proteins over plant proteins is significantly more pronounced in older adults (65+) than in younger adults, likely due to the 'leucine threshold'.

If you are over 65, ensure your plant proteins are high-leucine (e.g., soy, pea) or consider animal proteins to overcome age-related anabolic resistance. Younger adults can likely use either source effectively.

Individuals with high obesity genetic risk scores (GRS) experience greater initial weight loss during the first 6 months of behavioral interventions but are significantly more susceptible to weight regain during the subsequent 6 months compared to those with low GRS.

If you have a strong family history of obesity, expect to lose weight quickly when you start a diet, but be vigilant about maintenance. Your body may fight back harder to regain weight after the initial loss. Focus heavily on the strategies that help you maintain weight loss after the first 6 months, as this is where your genetic risk profile shows a tendency for regain.

Carbohydrate-restricted nutrition therapy (CRNT) supported by continuous remote care enables the deprescription of GLP-1 receptor agonists in people with type 2 diabetes without regression of glycemic control or body weight loss.

If you are on a GLP-1 drug (like Ozempic or Wegovy) for Type 2 Diabetes or weight, you do not necessarily have to take it forever. This study suggests that if you adopt a medically-supervised ketogenic diet (low carb, high healthy fat) and monitor your blood ketones, you may be able to stop the drug while keeping your weight and blood sugar stable. The key is that the diet reduces hunger hormones, doing the job the drug was doing, allowing you to step off the medication without regaining weight.

Combination pharmacotherapy for obesity is significantly more effective than monotherapy.

If one weight loss medication isn't working well, ask your doctor about combination therapies. They combine two drugs to target different pathways, often resulting in greater weight loss than a single drug.

Patients with Type 2 Diabetes Mellitus (T2DM) experience greater cardiovascular benefits and fewer adverse events from Tirzepatide compared to patients with obesity alone.

If you have both T2DM and obesity, or just T2DM, you may get more cardiovascular benefits and fewer side effects from Tirzepatide than if you have obesity alone. This suggests that your specific health condition plays a role in how well the medication works for you. Discuss your specific health profile with your doctor to understand what to expect.

GLP-1 receptor agonist therapy initiated at least one year after bariatric surgery produces additional significant weight loss with a favorable safety profile.

If you had bariatric surgery and are struggling with weight regain, GLP-1 medications (like semaglutide or dulaglutide) can help you lose more weight safely. Start with a low dose and work up slowly to minimize stomach issues. Combining the medication with a structured lifestyle program (like the VA's MOVE!) yields the best results.

GLP-1 receptor agonists (GLP-1RAs) improve reproductive outcomes in obese women with PCOS or unexplained infertility by reducing body weight, improving insulin sensitivity, and modulating endometrial immune balance (increasing Treg cells, decreasing pro-inflammatory cytokines, and restoring Th17/Treg balance).

For women with obesity and fertility issues (like PCOS), GLP-1 medications can help restore ovulation and improve the uterine environment by lowering inflammation. However, these drugs must be stopped before you conceive because they can harm the developing embryo. The goal is to use them during the preconception phase to fix metabolic and immune imbalances, then switch to pregnancy-safe management once pregnant.

MBS leads to marked improvements in sexual function for both men and women, including increased libido, erectile function, and hormonal normalization, typically within the first 12 months.

Expect significant improvements in sexual function and hormonal health within the first year after surgery. These changes are driven by weight loss and hormonal recalibration. Address any performance anxiety through counseling to maximize benefits.

GLP-1 receptor agonists (e.g., semaglutide) induce significant weight loss through hormonal mechanisms but carry a high risk of psychological dependency and rebound weight gain upon discontinuation, necessitating their use as temporary adjuncts to lifestyle interventions rather than standalone long-term solutions.

If you are using GLP-1 drugs, treat them as a temporary bridge to build sustainable habits, not a permanent solution. Prioritize resistance training and protein intake to protect muscle mass, as rapid weight loss without exercise increases frailty risk. Plan for discontinuation early by integrating behavioral therapy and dietary changes to prevent rebound weight gain and dependency.

Tirzepatide, a dual GLP-1/GIP receptor agonist, demonstrates significant efficacy in reducing body weight (over 20% in some cases) and improving glycemic control in patients with type 2 diabetes and obesity, suggesting therapeutic potential for women with Polycystic Ovary Syndrome (PCOS) who have comorbid obesity and insulin resistance.

For women with PCOS and obesity, tirzepatide offers a promising pharmacological tool to address both metabolic and reproductive symptoms. While not yet standard care for PCOS specifically, its ability to induce significant weight loss (>20%) and improve insulin sensitivity suggests it may help restore ovulation and reduce androgen levels. Treatment involves weekly subcutaneous injections starting at 2.5mg and titrating up to 15mg, ideally combined with lifestyle changes. Patients should be aware of potential GI side effects, though the drug's design aims to mitigate them.